Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis

Antinuclear antibodies (ANA) staining nuclear dot structures predominantly occur in primary biliary cirrhosis (PBC) patients and recognize the Sp100 and promyelocytic leukemia protein (PML). From retrospective analysis of sera from a clinically well‐defined Canadian series of 170 PBC patients included into a 24‐month therapeutic trial of ursodeoxycholic acid (UDCA), we report the prevalence of these ANA and their dynamics in the course of the disease. Using an enzyme‐linked immunosorbent assay (ELISA), anti‐Sp100 autoantibodies were shown in 35 (21%) patients. Thirty‐three patients (19%) had autoantibodies against PML as determined by indirect immunostaining of cells overexpressing PML. Altogether, anti‐nuclear dot autoantibodies were present in 25% of the 170 PBC patients. Their occurrence correlated with an unfavorable disease course, because these patients progressed significantly more frequently from early stages (I/II) to late stages (III/IV) within the 24‐month observation period (P < .05). During the course of the disease, the autoantibody levels against the Sp100 full‐length protein remained nearly constant in all 35 positive patients. However, 9 patients showed remarkable changes in Sp100 epitope recognition as revealed by ELISA and immunoblotting. When the occurrence of these changes and the treatment of the patients were compared retrospectively, it became evident that 8 of the 9 patients had received UDCA (42% of all Sp100‐positive patients treated with UDCA). These findings indicate subtle changes of the Sp100 epitope recognition pattern during the natural course of the disease and its induction or acceleration by UDCA treatment. This implies that UDCA can modulate immunoglobulin (Ig) expression not only quantitatively, but also qualitatively.

[1]  T. Sternsdorf,et al.  Nuclear dots: actors on many stages. , 1997, Immunobiology.

[2]  H. Will,et al.  Autoantibodies Against “Nuclear Dots” in Primary Biliary Cirrhosis , 1997, Seminars in liver disease.

[3]  T. Sternsdorf,et al.  Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). , 1996, European journal of biochemistry.

[4]  J. Courvalin,et al.  Specificity and sensitivity of gp210 autoantibodies detected using an enzyme‐linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis , 1996, Hepatology.

[5]  J. Węsierska‐Gądek,et al.  Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. , 1996, Gastroenterology.

[6]  Y. Makino,et al.  Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. , 1996, Journal of immunology.

[7]  P. Pandolfi,et al.  The acute promyelocytic leukaemia-associated PML gene is induced by interferon. , 1995, Oncogene.

[8]  T. Sternsdorf,et al.  Two Nuclear Dot‐Associated Proteins, PML and SplOO, are Often Co‐Autoimmunogenic in Patients with Primary Biliary Cirrhosis , 1995, Scandinavian journal of immunology.

[9]  Charles E. Kahn,et al.  primary biliary cirrhosis , 1995 .

[10]  U. Steinbrecher,et al.  The canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis , 1994, Hepatology.

[11]  N. Stuurman,et al.  The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.

[12]  R. Evans,et al.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein , 1994, Cell.

[13]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[14]  G. Maul,et al.  Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). , 1993, The Journal of general virology.

[15]  M. Snyder,et al.  Nuclear dot antigens may specify transcriptional domains in the nucleus , 1993, Molecular and cellular biology.

[16]  F. Lacaille,et al.  The immunosuppressive effect of ursodeoxycholic acid: A comparative in vitro study on human peripheral blood mononuclear cells , 1993, Hepatology.

[17]  A. Lamond,et al.  The coiled body. , 1993, Trends in cell biology.

[18]  H. Will,et al.  IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. , 1992, Journal of immunology.

[19]  H. Will,et al.  Autoantibodies to the Nuclear Sp100 Protein in Primary Biliary Cirrhosis and Associated Diseases: Epitope Specificity and Immunoglobulin Class Distribution , 1992, Scandinavian journal of immunology.

[20]  Y. Calmus,et al.  Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor–α production by monocytes , 1992, Hepatology.

[21]  Y. Matsumura,et al.  Immunomodulatory effects of ursodeoxycholic acid on immune responses , 1992, Hepatology.

[22]  M. Gossen,et al.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Ascoli,et al.  Identification of a novel nuclear domain , 1991, The Journal of cell biology.

[24]  H. Will,et al.  Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. , 1990, Journal of immunology.

[25]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[26]  G. Blobel,et al.  Identification and characterization of autoantibodies against the nuclear envelope lamin B receptor from patients with primary biliary cirrhosis , 1990, The Journal of experimental medicine.

[27]  D. Dhumeaux,et al.  Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis: A clinical and immune-logical study of a series of 150 patients with primary biliary cirrhosis , 1990 .

[28]  R. Sprengel,et al.  Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein , 1990, Journal of virology.

[29]  P. Gane,et al.  Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid , 1990, Hepatology.

[30]  F. BordaCelaya,et al.  [Primary biliary cirrhosis]. , 1989, Anales de medicina interna.

[31]  I. Mackay,et al.  Reactivity of primary biliary cirrhosis sera with a human fetal liver cDNA clone of branched‐chain α‐keto acid dehydrogenase dihydrolipoamide acyltransferase, the 52 kD mitochondrial autoantigen , 1989, Hepatology.

[32]  J. Guest,et al.  Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Coppel,et al.  Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Plana,et al.  Autoantibodies against nuclear envelope‐associated proteins in primary biliary cirrhosis , 1988, Hepatology.

[35]  R. Coppel,et al.  Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. , 1988, Arthritis and rheumatism.

[36]  R. Klein,et al.  11 Immunology of primary biliary cirrhosis , 1987 .

[37]  E. Penner,et al.  Autoimmune sera recognize a 100 kD nuclear protein antigen (sp-100). , 1987, Clinical and experimental immunology.

[38]  E. Christensen,et al.  Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients , 1980 .

[39]  R. Wozniak,et al.  Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. , 1994, Gastroenterology.

[40]  E. Tan,et al.  Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. , 1989, Advances in immunology.